Comprehensive analysis of glycolytic enzymes as therapeutic targets in the treatment of glioblastoma

PLoS ONE

Volumn 10, Issue 5, 2015, Pages

  Sanzey, Morgane ^a   Abdul Rahim, Siti Aminah ^a   Oudin, Anais ^a   Dirkse, Anne ^a   Kaoma, Tony ^a   Vallar, Laurent ^a   Herold Mende, Christel ^b   Bjerkvig, Rolf ^a,c   Golebiewska, Anna ^a   Niclou, Simone P ^a,c  

^a LUXEMBOURG INSTITUTE OF HEALTH   (Luxembourg)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c UNIVERSITY OF BERGEN   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

6 PHOSPHOFRUCTOKINASE; ALDOLASE A; CLOTRIMAZOLE; ENOLASE; FRUCTOSE BISPHOSPHATE ALDOLASE; GLYCOLYTIC ENZYME; HEXOKINASE; ISOENZYME; PHOSPHOGLYCERATE MUTASE; PHOSPHOGLYCERATE MUTASE 1; PYRUVATE DEHYDROGENASE KINASE; PYRUVATE DEHYDROGENASE KINASE 1; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG;

ADAPTATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG TARGETING; ENZYME ANALYSIS; GENE SILENCING; GLIOBLASTOMA; GLYCOLYSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOXIA; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; SURVIVAL; TUMOR ESCAPE; TUMOR XENOGRAFT; ANIMAL; BRAIN NEOPLASMS; CELL HYPOXIA; CELL PROLIFERATION; CELL SURVIVAL; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOLOGY; SURVIVAL ANALYSIS; TUMOR GENE; UPREGULATION;

MUS;

ANIMALS; BRAIN NEOPLASMS; CELL HYPOXIA; CELL PROLIFERATION; CELL SURVIVAL; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; GENES, NEOPLASM; GLIOBLASTOMA; GLYCOLYSIS; HUMANS; MICE; MOLECULAR TARGETED THERAPY; PHOSPHOFRUCTOKINASE-1; SURVIVAL ANALYSIS; UP-REGULATION;

EID: 84929120305     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0123544     Document Type: Article

References (45)

1. Weller M, Cloughesy T, Perry JR, Wick W. Standards of care for treatment of recurrent glioblastoma - are we there yet? Neuro-oncology. 2013; 15(1):4-27. doi: 10.1093/neuonc/nos273 PMID: 23136223
2. Carmeliet P, Jain RK. Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nature reviews Drug discovery. 2011; 10(6):417-27. doi: 10.1038/nrd3455 PMID: 21629292
3. Gilbert MR, Dignam JJ, Armstrong TS, Wefel JS, Blumenthal DT, Vogelbaum MA, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med. 2014; 370(8):699-708. doi: 10. 1056/NEJMoa1308573 PMID: 24552317
4. Chinot OL, Wick W, Cloughesy T. Bevacizumab for newly diagnosed glioblastoma. N Engl J Med. 2014; 370(21):2049. doi: 10.1056/NEJMc1402987#SA1 PMID: 24860870
5. Plate KH, Scholz A, Dumont DJ. Tumor angiogenesis and anti-angiogenic therapy in malignant gliomas revisited. Acta neuropathologica. 2012; 124(6):763-75. doi: 10.1007/s00401-012-1066-5 PMID: 23143192
6. Keunen O, Johansson M, Oudin A, Sanzey M, Rahim SA, Fack F, et al. Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma. Proceedings of the National Academy of Sciences of the United States of America. 2011; 108(9):3749-54. doi: 10.1073/pnas.1014480108 PMID: 21321221
7. Fack F, Espedal H, Keunen O, Golebiewska A, Obad N, Harter PN, et al. Bevacizumab treatment induces metabolic adaptation toward anaerobic metabolism in glioblastomas. Acta neuropathologica. 2014.
8. Stieber D, Abdul Rahim SA, Niclou SP. Novel ways to target brain tumour metabolism. Expert Opin Ther Targets. 2011; 15(10):1227-39. doi: 10.1517/14728222.2011.588211 PMID: 21635150
9. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009; 324(5930):1029-33. doi: 10.1126/science.1160809 PMID: 19460998
10. Chen W. Clinical applications of PET in brain tumors. J Nucl Med. 2007; 48(9):1468-81. PMID: 17704239
11. Wolf A, Agnihotri S, Munoz D, Guha A. Developmental profile and regulation of the glycolytic enzyme hexokinase 2 in normal brain and glioblastoma multiforme. Neurobiol Dis. 2011; 44(1):84-91. doi: 10. 1016/j.nbd.2011.06.007 PMID: 21726646
12. Gao H, Yu B, Yan Y, Shen J, Zhao S, Zhu J, et al. Correlation of expression levels of ANXA2, PGAM1, and CALR with glioma grade and prognosis. J Neurosurg. 2013; 118(4):846-53. doi: 10.3171/2012.9. JNS112134 PMID: 23082878
13. Muller FL, Colla S, Aquilanti E, Manzo VE, Genovese G, Lee J, et al. Passenger deletions generate therapeutic vulnerabilities in cancer. Nature. 2012; 488(7411):337-42. doi: 10.1038/nature11331 PMID: 22895339
14. Mazurek S, Boschek CB, Hugo F, Eigenbrodt E. Pyruvate kinase type M2 and its role in tumor growth and spreading. Semin Cancer Biol. 2005; 15(4):300-8. PMID: 15908230
15. Christofk HR, Vander Heiden MG, Harris MH, Ramanathan A, Gerszten RE, Wei R, et al. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature. 2008; 452(7184):230-3. doi: 10.1038/nature06734 PMID: 18337823
16. Velpula KK, Bhasin A, Asuthkar S, Tsung AJ. Combined targeting of PDK1 and EGFR triggers regression of glioblastoma by reversing the Warburg effect. Cancer Res. 2013; 73(24):7277-89. doi: 10.1158/ 0008-5472.CAN-13-1868 PMID: 24148623
17. Campos B, Wan F, Farhadi M, Ernst A, Zeppernick F, Tagscherer KE, et al. Differentiation therapy exerts antitumor effects on stem-like glioma cells. Clin Cancer Res. 2010; 16(10):2715-28. doi: 10.1158/ 1078-0432.CCR-09-1800 PMID: 20442299
18. Torsvik A, Stieber D, Enger PO, Golebiewska A, Molven A, Svendsen A, et al. U-251 revisited: genetic drift and phenotypic consequences of long-term cultures of glioblastoma cells. Cancer medicine. 2014; 3(4):812-24. doi: 10.1002/cam4.219 PMID: 24810477
19. Golebiewska A, Bougnaud S, Stieber D, Brons NH, Vallar L, Hertel F, et al. Side population in human glioblastoma is non-tumorigenic and characterizes brain endothelial cells. Brain. 2013; 136(Pt 5):1462-75. doi: 10.1093/brain/awt025 PMID: 23460667
20. Benjamini Y, H Y. Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. Journal of the Royal Statistical Society. 1995; 57(1):289-300.
21. Dennis G Jr, Sherman BT, Hosack DA, Yang J, Gao W, Lane HC, et al. DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol. 2003; 4(5):P3. PMID: 12734009
22. Supek F, Bosnjak M, Skunca N, Smuc T. REVIGO summarizes and visualizes long lists of gene ontology terms. PloS one. 2011; 6(7):e21800. doi: 10.1371/journal.pone.0021800 PMID: 21789182
23. Ahmed BY, Chakravarthy S, Eggers R, Hermens WT, Zhang JY, Niclou SP, et al. Efficient delivery of Cre-recombinase to neurons in vivo and stable transduction of neurons using adeno-associated and lentiviral vectors. BMC Neurosci. 2004; 5:4. PMID: 15005815
24. Niclou SP, Danzeisen C, Eikesdal HP, Wiig H, Brons NH, Poli AM, et al. A novel eGFP-expressing immunodeficient mouse model to study tumor-host interactions. Faseb J. 2008; 22(9):3120-8. doi: 10. 1096/fj.08-109611 PMID: 18495755
25. Lal A, Peters H, St Croix B, Haroon ZA, Dewhirst MW, Strausberg RL, et al. Transcriptional response to hypoxia in human tumors. J Natl Cancer Inst. 2001; 93(17):1337-43. PMID: 11535709
26. Chi JT, Wang Z, Nuyten DS, Rodriguez EH, Schaner ME, Salim A, et al. Gene expression programs in response to hypoxia: cell type specificity and prognostic significance in human cancers. PLoS Med. 2006; 3(3):e47. PMID: 16417408
27. Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009; 4(1):44-57. doi: 10.1038/nprot.2008.211 PMID: 19131956
28. Huang da W, Sherman BT, Lempicki RA. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic acids research. 2009; 37(1):1-13. doi: 10.1093/ nar/gkn923 PMID: 19033363
29. Du J, Yuan Z, Ma Z, Song J, Xie X, Chen Y. KEGG-PATH: Kyoto encyclopedia of genes and genomes-based pathway analysis using a path analysis model. Molecular bioSystems. 2014; 10(9):2441-7. doi: 10.1039/c4mb00287c PMID: 24994036
30. Kathagen A, Schulte A, Balcke G, Phillips HS, Martens T, Matschke J, et al. Hypoxia and oxygenation induce a metabolic switch between pentose phosphate pathway and glycolysis in glioma stem-like cells. Acta neuropathologica. 2013; 126(5):763-80. doi: 10.1007/s00401-013-1173-y PMID: 24005892
31. Zhang X, Varin E, Allouche S, Lu Y, Poulain L, Icard P. Effect of citrate on malignant pleural mesothelioma cells: a synergistic effect with cisplatin. Anticancer Res. 2009; 29(4):1249-54. PMID: 19414371
32. Marcondes MC, Sola-Penna M, Zancan P. Clotrimazole potentiates the inhibitory effects of ATP on the key glycolytic enzyme 6-phosphofructo-1-kinase. Arch Biochem Biophys. 2010; 497(1-2):62-7. doi: 10.1016/j.abb.2010.03.013 PMID: 20346906
33. Ganapathy-Kanniappan S, Vali M, Kunjithapatham R, Buijs M, Syed LH, Rao PP, et al. 3-bromopyruvate: a new targeted antiglycolytic agent and a promise for cancer therapy. Curr Pharm Biotechnol. 2010; 11(5):510-7. PMID: 20420565
34. De Witt Hamer PC, Van Tilborg AA, Eijk PP, Sminia P, Troost D, Van Noorden CJ, et al. The genomic profile of human malignant glioma is altered early in primary cell culture and preserved in spheroids. Oncogene. 2008; 27(14):2091-6. PMID: 17934519
35. Hirschhaeuser F, Menne H, Dittfeld C, West J, Mueller-Klieser W, Kunz-Schughart LA. Multicellular tumor spheroids: an underestimated tool is catching up again. Journal of biotechnology. 2010; 148- (1):3-15. doi: 10.1016/j.jbiotec.2010.01.012 PMID: 20097238
36. Goidts V, Bageritz J, Puccio L, Nakata S, Zapatka M, Barbus S, et al. RNAi screening in glioma stemlike cells identifies PFKFB4 as a key molecule important for cancer cell survival. Oncogene. 2012; 31- (27):3235-43. doi: 10.1038/onc.2011.490 PMID: 22056879
37. Bonnet S, Archer SL, Allalunis-Turner J, Haromy A, Beaulieu C, Thompson R, et al. A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. Cancer cell. 2007; 11(1):37-51. PMID: 17222789
38. Sutendra G, Michelakis ED. Pyruvate dehydrogenase kinase as a novel therapeutic target in oncology. Frontiers in oncology. 2013; 3:38. doi: 10.3389/fonc.2013.00038 PMID: 23471124
39. Michelakis ED, Sutendra G, Dromparis P, Webster L, Haromy A, Niven E, et al. Metabolic modulation of glioblastoma with dichloroacetate. Science translational medicine. 2010; 2(31):31ra4.
40. Kumar K, Wigfield S, Gee HE, Devlin CM, Singleton D, Li JL, et al. Dichloroacetate reverses the hypoxic adaptation to bevacizumab and enhances its antitumor effects in mouse xenografts. Journal of molecular medicine. 2013; 91(6):749-58. doi: 10.1007/s00109-013-0996-2 PMID: 23361368
41. Ren F, Wu H, Lei Y, Zhang H, Liu R, Zhao Y, et al. Quantitative proteomics identification of phosphoglycerate mutase 1 as a novel therapeutic target in hepatocellular carcinoma. Mol Cancer. 2010; 9:81. doi: 10.1186/1476-4598-9-81 PMID: 20403181
42. Yan T, Skaftnesmo KO, Leiss L, Sleire L, Wang J, Li X, et al. Neuronal markers are expressed in human gliomas and NSE knockdown sensitizes glioblastoma cells to radiotherapy and temozolomide. BMC Cancer. 2011; 11:524. doi: 10.1186/1471-2407-11-524 PMID: 22185371
43. Wolf A, Agnihotri S, Micallef J, Mukherjee J, Sabha N, Cairns R, et al. Hexokinase 2 is a key mediator of aerobic glycolysis and promotes tumor growth in human glioblastoma multiforme. J Exp Med. 2011; 208(2):313-26. doi: 10.1084/jem.20101470 PMID: 21242296
44. Pastorino JG, Shulga N, Hoek JB. Mitochondrial binding of hexokinase II inhibits Bax-induced cytochrome c release and apoptosis. J Biol Chem. 2002; 277(9):7610-8. PMID: 11751859
45. Penso J, Beitner R. Clotrimazole and bifonazole detach hexokinase from mitochondria of melanoma cells. Eur J Pharmacol. 1998; 342(1):113-7. PMID: 9544799